Molecular Analysis of WWOX Expression Correlation with Proliferation and Apoptosis in Glioblastoma Multiforme

Overview

Journal J Neurooncol

Publisher Springer

Date 2010 Jun 11

PMID 20535528

Citations 17

Authors

Katarzyna Kosla

Elzbieta Pluciennik

Agata Kurzyk

Dorota Jesionek-Kupnicka

Radzislaw Kordek

Piotr Potemski

Andrzej K Bednarek

Affiliations

Soon will be listed here.

Abstract

Glioblastoma multiforme is the most common type of primary brain tumor in adults. WWOX is a tumor suppressor gene involved in carcinogenesis and cancer progression in many different neoplasms. Reduced WWOX expression is associated with more aggressive phenotype and poor patient outcome in several cancers. We investigated alternations of WWOX expression and its correlation with proliferation, apoptosis and signal trafficking in 67 glioblastoma multiforme specimens. Moreover, we examined the level of WWOX LOH and methylation status in WWOX promoter region. Our results suggest that loss of heterozygosity (relatively frequent in glioblastoma multiforme) along with promoter methylation may decrease the expression of this tumor suppressor gene. Our experiment revealed positive correlations between WWOX and Bcl2 and between WWOX and Ki67. We also confirmed that WWOX is positively correlated with ErbB4 signaling pathway in glioblastoma multiforme.

Citing Articles

Molecular landscapes of glioblastoma cell lines revealed a group of patients that do not benefit from tumor suppressor expression.

Kaluzinska-Kolat Z, Kolat D, Kosla K, Pluciennik E, Bednarek A Front Neurosci. 2023; 17:1260409.

PMID: 37781246 PMC: 10540236. DOI: 10.3389/fnins.2023.1260409.

WWOX and metabolic regulation in normal and pathological conditions.

Baryla I, Kosla K, Bednarek A J Mol Med (Berl). 2022; 100(12):1691-1702.

PMID: 36271927 PMC: 9691486. DOI: 10.1007/s00109-022-02265-5.

ErbB4 in the brain: Focus on high grade glioma.

Pitcher J, Alexander N, Miranda P, Johns T Front Oncol. 2022; 12:983514.

PMID: 36119496 PMC: 9471956. DOI: 10.3389/fonc.2022.983514.

The gene in brain development and pathology.

Kosla K, Kaluzinska Z, Bednarek A Exp Biol Med (Maywood). 2020; 245(13):1122-1129.

PMID: 32389029 PMC: 7400721. DOI: 10.1177/1535370220924618.

The Gene Influences Cellular Pathways in the Neuronal Differentiation of Human Neural Progenitor Cells.

Kosla K, Pluciennik E, Styczen-Binkowska E, Nowakowska M, Orzechowska M, Bednarek A Front Cell Neurosci. 2019; 13:391.

PMID: 31543760 PMC: 6730490. DOI: 10.3389/fncel.2019.00391.

References

Qin H, Iliopoulos D, Semba S, Fabbri M, Druck T, Volinia S . A role for the WWOX gene in prostate cancer. Cancer Res. 2006; 66(13):6477-81. DOI: 10.1158/0008-5472.CAN-06-0956. View

Pfaffl M, Horgan G, Dempfle L . Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002; 30(9):e36. PMC: 113859. DOI: 10.1093/nar/30.9.e36. View

Driouch K, Prydz H, Monese R, Johansen H, Lidereau R, Frengen E . Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene. 2002; 21(12):1832-40. DOI: 10.1038/sj.onc.1205273. View

Aqeilan R, Kuroki T, Pekarsky Y, Albagha O, Trapasso F, Baffa R . Loss of WWOX expression in gastric carcinoma. Clin Cancer Res. 2004; 10(9):3053-8. DOI: 10.1158/1078-0432.ccr-03-0594. View

Strik H, Deininger M, Streffer J, Grote E, Wickboldt J, Dichgans J . BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry. 1999; 67(6):763-8. PMC: 1736652. DOI: 10.1136/jnnp.67.6.763. View

Sbrana I, Veroni F, Nieri M, Puliti A, Barale R . Chromosomal fragile sites FRA3B and FRA16D show correlated expression and association with failure of apoptosis in lymphocytes from patients with thyroid cancer. Genes Chromosomes Cancer. 2006; 45(5):429-36. DOI: 10.1002/gcc.20305. View

Gourley C, Paige A, Taylor K, Scott D, Francis N, Rush R . WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear. Int J Oncol. 2005; 26(6):1681-1689. PMC: 4166600. DOI: 10.3892/ijo.26.6.1681. View

Aqeilan R, Hagan J, de Bruin A, Rawahneh M, Salah Z, Gaudio E . Targeted ablation of the WW domain-containing oxidoreductase tumor suppressor leads to impaired steroidogenesis. Endocrinology. 2008; 150(3):1530-5. PMC: 2654736. DOI: 10.1210/en.2008-1087. View

Yendamuri S, Kuroki T, Trapasso F, Henry A, Dumon K, Huebner K . WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res. 2003; 63(4):878-81. View

10.

Weller M, Malipiero U, Aguzzi A, Reed J, Fontana A . Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest. 1995; 95(6):2633-43. PMC: 295946. DOI: 10.1172/JCI117965. View

11.

Kuroki T, Trapasso F, Shiraishi T, Alder H, Mimori K, Mori M . Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res. 2002; 62(8):2258-60. View

12.

Lei P, Zhang Z, Shen L, Li J, Zou Q, Zhang H . Expression and hypermethylation of p27 kip1 in hepatocarcinogenesis. World J Gastroenterol. 2005; 11(29):4587-91. PMC: 4398714. DOI: 10.3748/wjg.v11.i29.4587. View

13.

Caldeira J, Prando E, Quevedo F, Neto F, Rainho C, Rogatto S . CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer. 2006; 6:48. PMC: 1523210. DOI: 10.1186/1471-2407-6-48. View

14.

Ishii H, Vecchione A, Furukawa Y, Sutheesophon K, Han S, Druck T . Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol Cancer Res. 2003; 1(13):940-7. View

15.

Ishii H, Furukawa Y . Alterations of common chromosome fragile sites in hematopoietic malignancies. Int J Hematol. 2004; 79(3):238-42. DOI: 10.1532/ijh97.03145. View

16.

Jones F . HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer. J Mammary Gland Biol Neoplasia. 2008; 13(2):247-58. PMC: 2442669. DOI: 10.1007/s10911-008-9076-6. View

17.

Chinot O, Ochi C, Gambarelli D, Dufour H, Figarella-Branger D . Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol Appl Neurobiol. 1998; 24(5):381-8. DOI: 10.1046/j.1365-2990.1998.00137.x. View

18.

Chen T, Sahin A, Aldaz C . Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor suppressor gene region. Cancer Res. 1996; 56(24):5605-9. View

19.

Nagane M, Levitzki A, Gazit A, Cavenee W, Huang H . Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A. 1998; 95(10):5724-9. PMC: 20446. DOI: 10.1073/pnas.95.10.5724. View

20.

Aqeilan R, Croce C . WWOX in biological control and tumorigenesis. J Cell Physiol. 2007; 212(2):307-10. DOI: 10.1002/jcp.21099. View